RCSI Study: Urgent Need for Public Health Policies on E-Cigarettes

Regulations by 2FIRSTS.ai
May.09.2024
RCSI Study: Urgent Need for Public Health Policies on E-Cigarettes
A recent study from RCSI suggests urgent need for public health policies regarding the harmful chemicals in e-cigarettes.

According to The Journal on May 8th, a recent study by the Royal College of Surgeons in Ireland (RCSI) has highlighted the urgent need for public health policies concerning e-cigarettes.

 

This study indicates that many of the chemicals used to flavor e-cigarettes are harmful when inhaled after being heated. A total of 127 harmful chemicals were classified as "acute toxicity", 153 were considered "health hazards", and another 225 were classified as "irritants".

 

The report's author, Donal O'Shea, stated, "Before the situation worsens, we hope to understand the potential impacts of flavored e-cigarettes on the health of a large number of users. Prolonged exposure to chemicals in e-cigarettes may lead to a new wave of chronic disease sufferers emerging over the next 15 to 20 years.

 

Donald called for regulation of e-cigarette devices.

 

I believe that we need to regulate e-cigarette devices themselves, including disposable e-cigarettes and reusable e-cigarettes, as well as the temperature types they can achieve and proper disposal methods.

 

At the same time, Donald believes that British Prime Minister Rishi Sunak's announcement to ban disposable e-cigarettes from April 2025 will not be effective. He also stated that using e-cigarettes to quit smoking is "controversial" and not a method recommended by the Health and Safety Executive (HSE).

 

Increasing control over environments such as pharmacies may help people who are looking to quit smoking. Unfortunately, comprehensive bans have rarely been effective anywhere in the world.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
The FDA has added Glas products to its authorized electronic nicotine delivery systems (ENDS) list, granting Marketing Granted Orders (MGOs) to the Glas G DEVICE and a BLONDE TOBACCO pod. The decision expands the number of FDA-authorized ENDS products to 41, marking the first new authorization since Juul’s approvals in July 2025. However, widely anticipated non-tobacco flavored products were not approved.
Mar.13
Special Report|Reynolds’ 337 Patent Case Ends, but a Harsher 337 Compliance Battle Now Targets the Entire Vape Supply Chain
Special Report|Reynolds’ 337 Patent Case Ends, but a Harsher 337 Compliance Battle Now Targets the Entire Vape Supply Chain
The U.S. International Trade Commission (ITC) has terminated Investigation 337-TA-1410 after invalidating key vape patent claims asserted by R.J. Reynolds Vapor Company, removing the immediate risk of import bans for dozens of companies. However, a new case—337-TA-1486—has already opened a more consequential legal front, shifting the focus from patent disputes to regulatory compliance across the vape supply chain, including PACT Act reporting, tax compliance, and FDA marketing authorization.
BAT
Mar.11
Smoore, Distributors Move to Toss Cannabis Vape Price-Fixing Suit
Smoore, Distributors Move to Toss Cannabis Vape Price-Fixing Suit
Several vape manufacturers and distributors, including Shenzhen Smoore Technology Co. Ltd., Smoore International Holdings, 3Win Corp., Jupiter Research LLC, Canna Brand Solutions, and Greenlane Holdings Inc., have filed motions seeking dismissal of consumer claims in consolidated antitrust litigation in the U.S. District Court for the Northern District of California.
Events
Feb.24
UK Smoke-Free Generation Plan Backed by Both Houses of Parliament
UK Smoke-Free Generation Plan Backed by Both Houses of Parliament
Plans to create a smoke-free generation have received backing from both Houses of Parliament in the UK. On Monday, peers approved the Tobacco and Vapes Bill at its third reading, with the measure aiming to prevent anyone currently aged 17 or younger from ever buying cigarettes.
Mar.11 by 2FIRSTS.ai
Elfbar warns flavour bans could push over 50,000 Scottish vapers back to smoking
Elfbar warns flavour bans could push over 50,000 Scottish vapers back to smoking
Elfbar said restricting vape flavour choices—potentially under the Tobacco and Vapes Bill—could disrupt established quitting behaviours and increase relapse risk among former smokers. An Opinium survey commissioned by the company reported fruit and sweet flavours have risen in popularity among adult vapers quitting smoking in Scotland, with 62% now using them most often to quit, up from 34% in December 2024.
Feb.28 by 2FIRSTS.ai